Learning from Every Patient: The ASCO Research Enterprise- Enduring
Medical staff requested a series of lectures on the landscape of cancer care. Perspectives from thought leaders helps to revitalize the medical staff and develop innovative ideas on ways they can improve and impact patient care as well as research methods and technology, in addition to creating connections which may result in the eventual treatment options which may cure cancer.
The activity content is oriented to address the educational needs of physicians, nurses and all healthcare professionals interested in the subject matter.
- Identify current and leading-edge treatment options in cancer.
- Discuss clinical conundrums and possible solutions.
- Outline the safety and efficacy of recent clinical advances in the management of patients.
- Examine state-of-the-art information and skills necessary for treating patients.
This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.
As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse that could create a conflict of interest. Any potential conflicts relative to the previous disclosure have been resolved.
Presenter: Dr. Richard L. Schilsky has indicated that he receives Grant/Research Support from AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Genentech, Eli Lilly and Co., Merck and Pfizer.
City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.
Dr. Schilsky will be discussing the off-label or investigational use of Palbociclib, Pembrolizumab, Olaparib, Trastuzumab, Pertuzumab, Sunitinib, Temsirolimus, Cobimetinib, Vemurafenib, Cetuximab, Ipilimumab, Nivolumab and Regorafenib.
The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.
Learning from Every Patient: The ASCO Research Enterprise has received no commercial support.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1™ 1.25
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.25 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
- 1.25 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this Learning from Every Patient: The ASCO Research Enterprise- Enduring for a maximum of 1.25 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Attendance